Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

519
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
519
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

458
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
458
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

361
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
361
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

1.6K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.6K
Altered States of Awareness01:06

Altered States of Awareness

839
Altered states of consciousness represent significant deviations from one's normal mental state. These deviations can range from subtle changes in awareness to profound transformations in perception, thought processes, and sensory experiences. Altered states of consciousness can be triggered by various factors, including drug use, meditation, hypnosis, illness, or even intense fatigue.
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
839
Psychosurgery01:30

Psychosurgery

281
Psychosurgery, the surgical alteration or permanent removal of brain tissue to alleviate severe psychological conditions, stands as one of the most radical and controversial treatments in the history of mental health care. Its development and application have evolved significantly, marked by dramatic shifts in scientific understanding and ethical perspectives.
Historical Development of Psychosurgery
In the 1930s, Portuguese neurologist Antonio Egas Moniz introduced a surgical procedure designed...
281

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transvenous occlusion of a patent ductus arteriosus in a cat with the Amplatzer™ Vascular Plug II.

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology·2026
Same author

Depression and aging: insights from brain age prediction models.

Psychological medicine·2026
Same author

Repeatability and reproducibility of feline echocardiographic left ventricular myocardial area and left ventricular wall thickness measurement techniques.

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology·2026
Same author

Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.

The international journal of neuropsychopharmacology·2026
Same author

Exploring the Role of the Advanced Nurse Practitioner (ANP) Older Persons From the Perspective of the Interdisciplinary Team.

Journal of nursing management·2026
Same author

Climbing high: a mixed-methods feasibility study of climbing therapy for major depressive disorder in Ireland.

Irish journal of psychological medicine·2026

Related Experiment Video

Updated: Dec 11, 2025

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.5K

Psychedelic science in post-COVID-19 psychiatry.

J R Kelly1,2, M T Crockett3, L Alexander4

  • 1Department of Psychiatry, Trinity College Dublin, Dublin, Ireland.

Irish Journal of Psychological Medicine
|August 20, 2020
PubMed
Summary

Psilocybin therapy shows promise for treating mental health conditions like depression and addiction. Further research is exploring its efficacy and safety, especially in combination with other treatments for treatment-resistant depression.

Keywords:
COVID-19Coronavirusdepressionpsilocybinpsychedelicsselective serotonin reuptake inhibitorstreatment-resistant depression

More Related Videos

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

7.3K
Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure
08:20

Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure

Published on: January 18, 2021

4.3K

Related Experiment Videos

Last Updated: Dec 11, 2025

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.5K
Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

7.3K
Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure
08:20

Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure

Published on: January 18, 2021

4.3K

Area of Science:

  • Psychiatry
  • Neuroscience
  • Pharmacology

Background:

  • The COVID-19 pandemic may increase mental health issues, necessitating novel therapeutic strategies.
  • Psilocybin therapy is emerging as a potential transdiagnostic treatment for disorders characterized by maladaptive cognitive and behavioral patterns.
  • Existing research suggests psilocybin's efficacy in conditions such as depression, addiction, and obsessive-compulsive disorder.

Purpose of the Study:

  • To investigate the safety, efficacy, and optimal dosage of psilocybin therapy for treatment-resistant depression (TRD).
  • To compare the efficacy and mechanisms of psilocybin therapy against escitalopram, a selective serotonin reuptake inhibitor (SSRI).
  • To evaluate the safety and efficacy of psilocybin therapy when used concurrently with SSRIs in TRD patients.

Main Methods:

  • A phase 2b double-blind trial by COMPASS Pathways is assessing psilocybin therapy in antidepressant-free TRD patients.
  • The Psilodep-RCT study compares psilocybin therapy's efficacy and mechanisms to escitalopram.
  • A new COMPASS study in Dublin will investigate psilocybin therapy in conjunction with SSRIs for TRD.

Main Results:

  • Preliminary evidence indicates psilocybin therapy is a promising treatment for various psychiatric disorders.
  • Ongoing trials are determining the safety, efficacy, and optimal dosing of psilocybin for TRD.
  • Results comparing psilocybin therapy to escitalopram are pending publication.

Conclusions:

  • Psilocybin therapy holds potential as a therapeutic option for psychiatric disorders in the post-COVID-19 era.
  • Further research is crucial to understand the full potential and application of psilocybin therapy.
  • Investigating psilocybin therapy in combination with SSRIs could inform future clinical practice for TRD.